The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Phosphorothioate Oligodeoxynucleotides: What Is Their Origin and What Is Unique About Them?
Abstract
The development of nucleoside phosphorothioates is described in its historical context. Examples of the interaction of phosphorothioate groups, present either in oligodeoxynucleotides or in DNA, with nucleases are presented. The structural features responsible for the resistance of the phosphorothioates toward degradation by nucleases are discussed, as are the possible reasons for the high-affinity interaction of phosphorothioate oligodeoxynucleotides with certain proteins.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A general two-metal-ion mechanism for catalytic RNA
Steitz, T. A., & Steitz, J. A. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.14.6498 · Cited by 1,171 · cited 1×
“As many enzymes catalyzing phosphoryl transfer reactions follow the two-metal ion mecha¬ nism (Steitz and Steitz, 1993), the explanation given for the dif¬ ference in reactivity of phosphates and phosphorothioates for the Klenow enzyme might be applicable to other classes of en¬ zymes as well.”
Pearson, R. G. (1966) · Science · doi:10.1126/science.151.3707.172 · Cited by 979
Eckstein, F. (1985) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.54.070185.002055 · Cited by 849
Self-citationTaylor, W. J., Ott, J., & Eckstein, F. (1985) · Nucleic Acids Research · doi:10.1093/nar/13.24.8765 · Cited by 833
Self-citationThe 2.2 Å crystal structure of transducin-α complexed with GTPγS
Noel, J. P., Hamm, H. E., & Sigler, P. B. (1993) · Nature · doi:10.1038/366654a0 · Cited by 798
Nakamaye, K. L., & Eckstein, F. (1986) · Nucleic Acids Research · doi:10.1093/nar/14.24.9679 · Cited by 547
Self-citationMatsukura, M., Shinozuka, K., Zon, G., Mitsuya, H., Reitz, M., Cohen, J. S., & Broder, S. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.21.7706 · Cited by 533
5′–3′ Exonucleases in phosphorothioate-based oligonucleotide-directed mutagenesis
Sayers, J. R., Schmidt, W., & Eckstein, F. (1988) · Nucleic Acids Research · doi:10.1093/nar/16.3.791 · Cited by 326
Self-citationMODIFIED OLIGONUCLEOTIDES: Synthesis and Strategy for Users
Verma, S., & Eckstein, F. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.99 · Cited by 315
Self-citationPecoraro, V. L., Hermes, J. D., & Cleland, W. W. (1984) · Biochemistry · doi:10.1021/bi00317a026 · Cited by 291
Cited by
Bennett, C. F., & Swayze, E. E. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105654 · Cited by 1,374
Antisense technologies: Improvement through novel chemical modifications
Kurreck, J. (2003) · European Journal of Biochemistry · doi:10.1046/j.1432-1033.2003.03555.x · Cited by 1,006
siRNAs: applications in functional genomics and potential as therapeutics
Dorsett, Y., & Tuschl, T. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1345 · Cited by 909
Crooke, S. T., Witztum, J. L., Bennett, C. F., & Baker, B. F. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.004 · Cited by 841
Antisense technology: an overview and prospectus
Crooke, S. T., Baker, B. F., Crooke, R. M., & Liang, X.-H. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00162-z · Cited by 775
Prakash, T. P., Graham, M. J., Yu, J., Carty, R., Low, A., Chappell, A., Schmidt, K., Zhao, C., Aghajan, M., Murray, H. F., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku531 · Cited by 610
Designing Chemically Modified Oligonucleotides for Targeted Gene Silencing
Deleavey, G. F., & Damha, M. J. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.07.011 · Cited by 589
Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development
Dhuri, K., Bechtold, C., Quijano, E., Pham, H., Gupta, A., Vikram, A., & Bahal, R. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9062004 · Cited by 545
Swayze, E. E., Siwkowski, A. M., Wancewicz, E. V., Migawa, M. T., Wyrzykiewicz, T. K., Hung, G., Monia, B. P., & Bennett, A. C. F. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkl1071 · Cited by 469
Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense Agents
Vickers, T. A., Koo, S., Bennett, C. F., Crooke, S. T., Dean, N. M., & Baker, B. F. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210326200 · Cited by 461
ANTISENSE OLIGONUCLEOTIDES: FROM DESIGN TO THERAPEUTIC APPLICATION
Chan, J. H., Lim, S., & Wong, W. F. (2006) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2006.04403.x · Cited by 430
The Medicinal Chemistry of Therapeutic Oligonucleotides
Wan, W. B., & Seth, P. P. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00551 · Cited by 429
Röthlisberger, P., & Hollenstein, M. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.04.007 · Cited by 413
New Modalities for Challenging Targets in Drug Discovery
Valeur, E., Guéret, S. M., Adihou, H., Gopalakrishnan, R., Lemurell, M., Waldmann, H., Grossmann, T. N., & Plowright, A. T. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201611914 · Cited by 382
Phosphorothioate modified oligonucleotide–protein interactions
Crooke, S. T., Vickers, T. A., & Liang, X.-H. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa299 · Cited by 372
Antisense technology: A review
Crooke, S. T., Liang, X.-H., Baker, B. F., & Crooke, R. M. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100416 · Cited by 326
Therapeutic Oligonucleotides: State of the Art
Smith, C. I. E., & Zain, R. (2019) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021050 · Cited by 323
Renaud, J.-B., Boix, C., Charpentier, M., De Cian, A., Cochennec, J., Duvernois-Berthet, E., Perrouault, L., Tesson, L., Edouard, J., Thinard, R., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.02.018 · Cited by 301
Baumann, V., & Winkler, J. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.14.116 · Cited by 297
Perspectives on Chemistry and Therapeutic Applications of Locked Nucleic Acid (LNA)
Kaur, H., Babu, B. R., & Maiti, S. (2007) · Chemical Reviews · doi:10.1021/cr050266u · Cited by 285
Grunweller, A. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg409 · Cited by 269
Seth, P. P., Siwkowski, A., Allerson, C. R., Vasquez, G., Lee, S., Prakash, T. P., Wancewicz, E. V., Witchell, D., & Swayze, E. E. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801294h · Cited by 266
RNA‐PROTACs: Degraders of RNA‐Binding Proteins
Ghidini, A., Cléry, A., Halloy, F., Allain, F. H. T., & Hall, J. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202012330 · Cited by 197
Orlando, S. J., Santiago, Y., DeKelver, R. C., Freyvert, Y., Boydston, E. A., Moehle, E. A., Choi, V. M., Gopalan, S. M., Lou, J. F., Li, J., et al. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq512 · Cited by 174
Antisense oligonucleotides: treating neurodegeneration at the level of RNA
DeVos, S. L., & Miller, T. M. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0194-5 · Cited by 164
“The nonbridging phosphate oxygen atoms in natural nucleic acids are replaced with sulfur atoms, equipping ASOs with several important properties that support their use as a systemic drug [1].”
BackgroundPhosphorothioate backbone modifications of nucleotide-based drugs are potent platelet activators
Flierl, U., Nero, T. L., Lim, B., Arthur, J. F., Yao, Y., Jung, S. M., Gitz, E., Pollitt, A. Y., Zaldivia, M. T. K., Jandrot-Perrus, M., et al. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20140391 · Cited by 114
“The sulfur atom has a larger van der Waal’s radius (1.8 compared with 1.4 Å) and sulfur-phosphorus bond length (1.9 compared with 1.5 Å) than oxygen (Eckstein, 2000).”
InfluentialDNA methylation regulates neuronal glutamatergic synaptic scaling
Meadows, J. P., Guzman-Karlsson, M. C., Phillips, S., Holleman, C., Posey, J. L., Day, J. J., Hablitz, J. J., & Sweatt, J. D. (2015) · Science Signaling · doi:10.1126/scisignal.aab0715 · Cited by 111
Antisense drugs make sense for neurological diseases
Bennett, C. F., Kordasiewicz, H. B., & Cleveland, D. W. (2021) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010919-023738 · Cited by 108
Metadata
- Authors
- ECKSTEIN, F.
- Venue
- Antisense and Nucleic Acid Drug Development
- Publisher
- SAGE Publications
- Published
- 2000-04
- Volume
- 10
- Issue
- 2
- Pages
- 117-121
- ISSN
- 1087-2906 (ISSN-L)
- OpenAlex
- W2064808830
- Cited by
- 382
- References
- 29
- FWCI
- 3.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.